The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
|Videos|December 3, 2014
Care Transitions for Acute Coronary Syndrome Patients
Joe Moose, PharmD, of Moose Pharmacy, discusses the role of the pharmacist in care transitions for acute coronary syndrome patients.
Advertisement
Joe Moose, PharmD, of Moose Pharmacy, discusses the role of the pharmacist in care transitions for acute coronary syndrome patients.
This interview was recorded at the NCPA 2014 Annual Convention in Austin, Texas.
Advertisement
Related to this article
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Pharmacists make a difference in patients’ lives through MTM services.
The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Finerenone in Heart Failure: Evidence and Practice a Year Later
3
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
4
FDA Approves Zilucoplan Autoinjector for Myasthenia Gravis
5